Skip to content
Xylose
Xylo-pfan (xylose) is a small molecule pharmaceutical. Xylose was first approved as Xylo-pfan on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Xylose
Tradename
Company
Number
Date
Products
XYLOSELyne LaboratoriesN-018856 DISCN1987-03-26
1 products
XYLO-PFANSavage LaboratoriesN-017605 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
92 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E8411—147
AnesthesiaD000758—22116
ObesityD009765EFO_0001073E66.91——1—2
Postoperative nausea and vomitingD020250EFO_0004888———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1—1—24
Coronary artery diseaseD003324I25.1—21——3
Coronary artery bypassD001026EFO_0003776——2——2
Pulmonary surgical proceduresD013510——2——2
Post-cardiac arrest syndromeD000080942——1——1
Coronary diseaseD003327——1——1
Panic disorderD016584EFO_0004262F41.0—11——1
Post-traumatic stress disordersD013313EFO_0001358F43.1—11——1
Pulmonary embolismD011655EFO_0003827I26——1——1
Postoperative cognitive complicationsD000079690——1——1
Show 3 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.942——16
Idiopathic pulmonary fibrosisD054990J84.11212———3
Non-small-cell lung carcinomaD00228911——13
Brain hypoxia-ischemiaD020925EFO_1000846P91.612——13
Respiration disordersD012120J00-J9922———2
Covid-19D000086382U07.1—1——12
VapingD00007213711——12
Bronchiolitis obliteransD001989EFO_000718311——12
Colorectal neoplasmsD015179—1———1
DeliriumD003693R41.0—1———1
Show 10 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lung diseasesD008171EFO_0003818J98.41———12
Bipolar disorderD001714EFO_0000289F30.91————1
Major depressive disorderD003865EFO_0003761F221————1
Alzheimer diseaseD000544EFO_0000249F031————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Premature birthD047928EFO_0003917O60————11
Bronchopulmonary dysplasiaD001997P27.8————11
EmphysemaD004646EFO_0000464J43————11
CholelithiasisD002769EFO_0004799K80————11
CholecystitisD002764HP_0001082K81————11
Brain diseasesD001927HP_0001298G93.40————11
Marijuana smokingD008385————11
Marijuana useD000074609————11
Lung injuryD055370S27.30————11
InfectionsD007239EFO_0000544————11
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameXYLOSE
INN—
Description
D-xylopyranose is d-Xylose in its pyranose form.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
OC1OC[C@@H](O)[C@H](O)[C@H]1O
Identifiers
PDB—
CAS-ID58-86-6
RxCUI—
ChEMBL IDCHEMBL502135
ChEBI ID53455
PubChem CID135191
DrugBank—
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 40,695 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details